LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Johnson and Johnson

Închisă

SectorSănătate

151.29 1.18

Rezumat

Modificarea prețului

24h

Curent

Minim

149.01

Maxim

151.45

Indicatori cheie

By Trading Economics

Venit

7.6B

11B

Vânzări

-627M

22B

P/E

Medie Sector

17.146

56.602

EPS

2.77

Randament dividend

3.37

Marjă de profit

50.24

Angajați

138,100

EBITDA

9.7B

16B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.29% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.37%

2.45%

Următoarele câștiguri

16 iul. 2025

Data viitoare de dividende

10 iun. 2025

Următoarea dată ex-dividende

27 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-6.3B

371B

Deschiderea anterioară

150.11

Închiderea anterioară

151.29

Sentimentul știrilor

By Acuity

45%

55%

157 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Johnson and Johnson Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 mai 2025, 17:03 UTC

Câștiguri
Principalele dinamici ale pieței

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

15 apr. 2025, 15:12 UTC

Câștiguri

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 apr. 2025, 10:35 UTC

Top știri
Câștiguri

J&J Increases Outlook After Beating 1Q Expectations

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mai 2025, 09:30 UTC

Top știri

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

4 mai 2025, 04:05 UTC

Achiziții, Fuziuni, Preluări

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

18 apr. 2025, 11:00 UTC

Top știri

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 apr. 2025, 20:34 UTC

Câștiguri

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 apr. 2025, 18:24 UTC

Câștiguri

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 apr. 2025, 19:06 UTC

Câștiguri

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 apr. 2025, 18:52 UTC

Market Talk
Câștiguri

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 apr. 2025, 14:54 UTC

Câștiguri

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr. 2025, 13:19 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr. 2025, 11:52 UTC

Câștiguri

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr. 2025, 11:14 UTC

Câștiguri

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr. 2025, 10:51 UTC

Câștiguri

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 apr. 2025, 10:37 UTC

Top știri
Câștiguri

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 apr. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

Comparație

Modificare preț

Johnson and Johnson Așteptări

Obiectiv de preț

By TipRanks

13.29% sus

Prognoză pe 12 luni

Medie 169.5 USD  13.29%

Maxim 185 USD

Minim 153 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruJohnson and Johnson - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

15 ratings

7

Cumpărare

8

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

154.93 / 155.895Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

157 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.